Sign in Subscribe

FDA Signals Accelerated Approval Path for uniQure’s Huntington’s Gene Therapy AMT-130

uniQure receives positive FDA feedback for accelerated approval of its one-time gene therapy AMT-130 for Huntington’s disease. BLA submission planned for Q3 2026.

FDA Signals Accelerated Approval Path for uniQure’s Huntington’s Gene Therapy AMT-130
Credit: Sarah Silbiger/Getty Images
Already have an account? Sign in.